Learn to Quit-HIV Pilot Study
Early-phase Studies of a Tailored Evidence-Based Smoking Cessation mHealth App for Persons Living With HIV
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HIV-positive
- Currently engaged with an HIV care provider
- Self-report smoking 5 cigarettes or more per day during the past 30 days
- Age 18 years or older
- Current interest in quitting smoking
- Currently own a functioning Android or Apple smartphone
Exclusion Criteria:
- No desire to quit smoking
- Inability to attend study sessions
- Inability to provide informed consent
- Any medical condition or concomitant medication that could compromise subject safety or treatment, as determined by the Principal Investigators and/or Study Physician
- Presence of contraindications for nicotine patch
- Previous allergic reaction or hypersensitivity to nicotine patch (lifetime)
- Current use of nicotine replacement therapy or other smoking cessation treatment (e.g., bupropion, varenicline)
- Pregnant, planning to become pregnant, nursing, or becoming pregnant during the study
- Current untreated and unstable diagnosis of alcohol/substance abuse or dependence (eligible if past abuse/dependence and if receiving treatment and stable for >30 days)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Learn to Quit-HIV
A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
|
A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
Other Names:
All participants will receive an 8-week course of nicotine patches.
They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant.
This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
|
|
Active Comparator: QuitGuide
A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS (United States Department of Health and Human Services) Clinical Practice Guidelines.
This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
|
All participants will receive an 8-week course of nicotine patches.
They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant.
This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of Daily App Use
Time Frame: 3 months
|
Average duration of app use per arm over participants' 3 months of study participation
|
3 months
|
|
Frequency of App Use as Measured by Interactions Per Day
Time Frame: 3 months
|
Average frequency of app use per arm over participants' 3 months of study participation.
|
3 months
|
|
Participant Attrition at One Month
Time Frame: 1 month
|
Number of participants lost to follow-up at one month.
|
1 month
|
|
Participant Attrition at Two Months
Time Frame: 2 months
|
Number of participants lost-to-follow-up at two months.
|
2 months
|
|
Participant Attrition at Three Months
Time Frame: 3 month
|
Number of participants lost-to-follow-up at three months.
|
3 month
|
|
Recruitment as Measured by the Proportion of Goal Participants Consented
Time Frame: 1 year
|
Number of participants consented divided by goal of consenting 60 participants.
|
1 year
|
|
App Usability as Measured by the Systems Usability Scale
Time Frame: 1 month or next available time point if participant completed the measure at 3 months.
|
Average app usability scores as measured by the Systems Usability Scale.
The scale has a score range of 0 to 100 with higher scores representing better outcomes.
|
1 month or next available time point if participant completed the measure at 3 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction in Cigarettes Smoked Per Day
Time Frame: 3 months
|
Change in cigarettes smoked per day from baseline to the 12-week follow up.
Cigarettes smoked per day are measured with a self-report item at baseline and at the 3-month follow up.
This outcome is calculated as the difference between cigarettes smoked per day at baseline and the cigarettes smoked per day at the 3 month timepoint.
A positive and large values in this outcome indicate larger reductions in cigarettes smoked per day per group, indicating a more positive outcome.
A negative and large value indicate an increase in cigarettes smoked per day per group, indicating a clinically negative outcome.
|
3 months
|
|
Number of Quit Attempts
Time Frame: 1 month
|
Quit attempts defined as self-reported no smoking at all for 24 hours; assessed via a Timeline Followback procedure.
|
1 month
|
|
Number of Quit Attempts
Time Frame: 3 months
|
Quit attempts defined as self-reported no smoking at all for 24 hours; assessed via a Timeline Followback procedure.
|
3 months
|
|
7-day Point Prevalence Abstinence
Time Frame: 1 month
|
Percent of subjects in each group reporting 7-day point prevalence abstinence.
Abstinence is determined by a self-report of not smoking any tobacco product at all during the corresponding time frame period, AND by a result of less than 5 ppm in carbon monoxide breath testing.
If the participant does not meet both criteria, or if they do not provide data at the time-point they are not considered abstinent.
|
1 month
|
|
7-day Point Prevalence Abstinence
Time Frame: 3 months
|
Percent of subjects in each group reporting 7-day point prevalence abstinence.
Abstinence is determined by a self-report of not smoking any tobacco product at all during the corresponding time frame period, AND by a result of less than 5 ppm in carbon monoxide breath testing.
If the participant does not meet both criteria, or if they do not provide data at the time-point they are not considered abstinent.
|
3 months
|
|
Overall Adherence to Nicotine Replacement Therapy
Time Frame: baseline to 3 months
|
Reported as percent of participants who used the patch at least 80% of the days of the required 8 weeks.
Adherence determined by timeline follow back interview.
|
baseline to 3 months
|
|
Number of Participants With at Least One Adverse Event Determined to be Related to the Study Interventions
Time Frame: 3 months
|
Adverse events reported here will only include those that are determined to be related to the study interventions.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lauren Pacek, PhD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
Other Study ID Numbers
- Pro00104423
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.